Dec 16, 2022
|
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 22, 2022
|
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
|
Nov 16, 2022
|
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 16, 2022
|
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 4, 2022
|
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
|
Nov 3, 2022
|
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
|
Nov 3, 2022
|
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial
|
Nov 2, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Oct 31, 2022
|
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
|
Oct 27, 2022
|
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
|